Pharmacogenomics of Cardiac Arrhythmias and Impact on Drug Therapy

Cardiac Electrophysiology: Fourth Edition

Volumn , Issue , 2004, Pages 471-477

  Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954126795     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-7216-0323-8/50054-3     Document Type: Chapter

References (45)

1. Collins FS, Jegalian KG Deciphering the code of life. Sci Am 1999, 281:86-91.
2. Collins FS Shattuck lecture-Medical and societal consequences of the Human Genome Project. N Engl J Med 1999, 341:28-37.
3. Roden DM, George AL The genetic basis of variability in drug responses. Nat Rev Drug Discov 2002, 1:37-44.
4. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999, 39:361-398.
5. Zhang L, Brett CM, Giacomini KM Role of organic cation transporters in drug absorption and elimination. Annu Rev Pharmacol Toxicol 1998, 38:431-460.
6. Mayer U, Wagenaar E, Dorobek B, et al. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997, 100:2430-2436.
7. Dean M, Rzhetsky A, Allikmets R The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001, 11:1156-1166.
8. Guengerich FP Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999, 39:1-17.
9. Meyer UA, Zanger UM Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997, 37:269-296.
10. Innocenti F, Iyer L, Ratain MJ Pharmacogenetics: A tool for individualizing antineoplastic therapy. Clin Pharmacokinet 2000, 39:315-325.
11. Weinshilboum RM, Otterness DM, Szumlanski CL Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999, 39:19-52.
12. Woosley RL, Chen Y, Freiman JP, Gillis RA Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993, 269:1532-1536.
13. Wysowski DK, Bacsanyi J Cisapride and fatal arrhythmia. N Engl J Med 1996, 335:290-291.
14. Drolet B, Khalifa M, Daleau P, et al. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998, 97:204-210.
15. Fromm MF, Kim RB, Stein CM, et al. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999, 99:552-557.
16. Funck-Brentano C, Becquemont L, Kroemer HK, et al. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: Contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther 1994, 55:256-269.
17. Evers J, Eichelbaum M, Kroemer HK Unpredictability of flecainide plasma concentrations in patients with renal failure: Relation to side effects and sudden death?. Ther Drug Monit 1994, 16:349-351.
18. Kr: Implications for Torsades de Pointes and reverse use-dependence. Circulation 1996, 93:407-411.
19. Ks by the diuretic agent indapamide modulates cardiac electrophysiological effects of the class III antiarrhythmic drug dl-sotalol. J Pharmacol Exp Ther 1997, 283:148-156.
20. Lee JT, Kroemer HK, Silberstein DJ, et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med 1990, 322:1764-1768.
21. Aithal GP, Day CP, Kesteven PJ, Daly AK Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999, 353:717-719.
22. Kalow W Pharmacogenetics, pharmacogenomics, and pharmacobiology. Clin Pharmacol Ther 2001, 70:1-4.
23. McLeod HL, Evans WE Pharmacogenomics: Unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001, 41:101-121.
24. Evans WE, Relling MV Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999, 286:487-491.
25. Roses AD Pharmacogenetics and the practice of medicine. Nature 2000, 405:857-865.
26. Rothstein MA, Epps PG Ethical and legal implications of pharmacogenomics. Nat Rev Genet 2001, 2:228-231.
27. Wandel C, Witte JS, Hall JM, et al. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B5?-promoter region polymorphism. Clin Pharmacol Ther 2000, 68:82-91.
28. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001, 27:383-391.
29. Schuetz EG, Strom S, Yasuda K, et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters and cytochrome P450. J Biol Chem 2001, 276:39411-39418.
30. Schinkel AH, Smit JJM, van Tellingen O, et al. Disruption of the mouse mdr 1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77:491-502.
31. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000, 97:3473-3478.
32. Kim RB Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002, 34:47-54.
33. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001, 70:189-199.
34. Kr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999, 97:175-187.
35. Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 2000, 97:10613-10618.
36. Mitcheson JS, Chen J, Lin M, et al. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 2000, 97:12329-12333.
37. Donger C, Denjoy I, Berthet M, et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997, 96:2778-2781.
38. Yang P, Kanki H, Drolet B, et al. Allelic variants in long QT disease genes in patients with drug-associated Torsades de Pointes. Circulation 2002, 105:1943-1948.
39. Ks potassium channels. Circulation 1999, 100:I-495.
40. Splawski I, Timothy KW, Tateyama M, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002, 297:1333-1336.
41. Roden DM Taking the idio out of idiosyncratic-Predicting Torsades de Pointes. Pacing Clin Electrophysiol 1998, 21:1029-1034.
42. Alings M, Wilde A "Brugada" syndrome: Clinical data and suggested pathophysiological mechanism. Circulation 1999, 99:666-673.
43. Akiyama T, Pawitan Y, Greenberg H, et al. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1991, 68:1551-1555.
44. Spooner PM, Albert C, Benjamin EJ, et al. Sudden cardiac death, genes, and arrhythmogenesis: Consideration of new population and mechanistic approaches from a National Heart Lung and Blood Institute workshop, part I. Circulation 2001, 103:2361-2364.
45. Roden DM The problem, challenge, and opportunity of genetic heterogeneity in monogenic diseases predisposing to sudden death [editorial]. J Am Coll Cardiol 2002, 40:359.